Skip to content
Press Releases
Filter Releases
 
Press Releases
Nov 22, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has released its revised final 2017 Medicare reimbursement rate for the company's Afirma Gene Expression Classifier (GEC). As a result of Veracyte's reconsideration request, the agency ha...
PDF
Nov 21, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced the appointment of Keith Kennedy as chief financial officer. Mr. Kennedy, the former president and chief executive office...
PDF
Nov 15, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will participate in a fireside chat discussion at the Piper Jaffray 28th Annual Healthcare Conference on Tuesday, November 29, 2016 at 3:30 p.m. ET in New York, NY. The live...
PDF
Nov 3, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced financial results for the third quarter ended September 30, 2016 and provided an update on recent business progress. For the third quarter of 2016, revenue was $18.6 million, an increase of 51%, compared to $12.3 million for the third quarter of ...
PDF
Nov 2, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $6.00 per share. The gross proceeds to Veracyte from this offering, before deducting underwriting discounts and commissions and o...
PDF
Nov 1, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it has commenced an underwritten public offering of its common stock. All of the shares are being offered by Veracyte. In addition, Veracyte expects to grant the underwriters a 30-day option to purchase additional shares of its common stock ...
PDF
Oct 26, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced new data from a prospective, multicenter clinical utility study showing that use of the Percepta Bronchial Genomic Classifier to resolve inconclusive diagnostic results in patients undergoing evaluation for suspected lung cancer led to a signifi...
PDF
Oct 25, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced the launch of the Envisia Genomic Classifier at the CHEST Annual Meeting 2016 in Los Angeles. Envisia is expected to be the fir...
PDF
Oct 17, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today released preliminary unaudited financial results for the third quarter ended September 30, 2016. Third Quarter 2016 Prelimi...
PDF
Oct 13, 2016
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that external researchers will present data from three studies reinforcing the clinical impact and value of the company's Perce...
PDF
Page: First Previous
...
Next Last